Patent · US Active

Reducing the risk of cardiovascular events

US10828310B2 · kind B2 · utility

0Cited by

2References

8Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Nancy Cook Bruns · Kassel, DE
Frank Misselwitz · Heidelberg, DE
John Eikelboom · Kelmscott, AU
Stuart J. Connolly · Hamilton, CA
Salim Yusuf · Carlisle, CA

Key dates

Filing date	Jan 31, 2019
Grant date	Nov 10, 2020
Priority date	—
Expiry date	Jan 31, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P9/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Combination therapy with rivaroxaban and aspirin successfully reduces the risk of cardiovascular events in patients who have coronary artery disease and/or peripheral artery disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.